FLC
ZVSA

Fifth Lane Capital’s ZyVersa Therapeutics ZVSA Stock Holding History

Fifth Lane Capital’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-143
Closed -$496K – 383
2022
Q1 		$496K Buy
+143
New +$495K 0.3% 102

Other funds holding ZVSA

CM
Cohanzick Management Pleasantville, New York $231M AUM 3.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
RA
RiverPark Advisors New York $219M AUM 14.91% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return

Fifth Lane Capital's ZVSA Position: Q2 2022 in Review

Fifth Lane Capital sold out of ZyVersa Therapeutics (ZVSA) in Q2 2022, closing a stake of 143 shares — an estimated $496K sold.

Fifth Lane Capital first reported a position in ZVSA in Q1 2022 and held it in 1 quarter. The position peaked at $496K in Q1 2022. 24 funds tracked by Wall St. Rank hold ZVSA as of Q2 2022.

  • Fifth Lane Capital reported no remaining ZyVersa Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Fifth Lane Capital sold 143 ZyVersa Therapeutics shares in Q2 2022, an estimated $496K.
  • Fifth Lane Capital first reported a position in ZyVersa Therapeutics in Q1 2022 and held it in 1 quarter.
  • Fifth Lane Capital's ZyVersa Therapeutics position peaked at $496K in Q1 2022.
  • 24 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q2 2022.

Based on Fifth Lane Capital's 13F filing for Q2 2022, filed 15 Aug 2022.